EXACT Sciences Corp. (EXAS)

76.28
NASDAQ : Health Technology
Prev Close 74.99
Day Low/High 74.76 / 76.86
52 Wk Low/High 37.36 / 80.35
Avg Volume 2.39M
Exchange NASDAQ
Shares Outstanding 122.75M
Market Cap 9.21B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Don't Forget the Consumer: Cramer's 'Mad Money' Recap (Wednesday 8/22/18)

Don't Forget the Consumer: Cramer's 'Mad Money' Recap (Wednesday 8/22/18)

Jim Cramer says we have a $19 trillion economy, and two-thirds of it is based on consumer spending -- not manufacturing, or sales, or industry.

Exact Sciences And Pfizer Enter Into U.S. Promotion Agreement For Cologuard®

Exact Sciences And Pfizer Enter Into U.S. Promotion Agreement For Cologuard®

Collaboration is expected to drive Cologuard adoption through expanded sales and marketing efforts

Green Bay Packers And Cologuard Launch "Crossing The 50" Colon Cancer Awareness Campaign

Green Bay Packers And Cologuard Launch "Crossing The 50" Colon Cancer Awareness Campaign

Fans taking screening pledge can be entered to win luxury box tickets

Raytheon, Northrop Grumman, Zuora: 'Mad Money' Lightning Round

Raytheon, Northrop Grumman, Zuora: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Raytheon, Northrop Grumman, Zuora, Exact Sciences.

Apple's Trillion-Dollar Market Cap: Cramer's 'Mad Money' Recap (Thur 8/2/18)

Apple's Trillion-Dollar Market Cap: Cramer's 'Mad Money' Recap (Thur 8/2/18)

This trillion-dollar level is so meaningful, Jim Cramer says, because Apple may be the first company to get here, but it won't be the last. Get ready.

Tom Lehman Joins Forces With Fight Colorectal Cancer To Raise Awareness Of Nation's Second-Leading Cause Of Cancer Deaths

Tom Lehman Joins Forces With Fight Colorectal Cancer To Raise Awareness Of Nation's Second-Leading Cause Of Cancer Deaths

PGA TOUR Professional and Colon Cancer Survivor to Serve as Brand Ambassador for Fight CRC and Participate in Year-Long Public Service Announcement Campaign

Cologuard® Revenue Increased 78 Percent To $103 Million During Second Quarter

Cologuard® Revenue Increased 78 Percent To $103 Million During Second Quarter

- More than 10,000 healthcare providers ordered their initial Cologuard test during the second quarter, and nearly 121,000 have ordered since the test was launched

3 'Strong Buy' Healthcare Stocks Poised to Surge

3 'Strong Buy' Healthcare Stocks Poised to Surge

Here are the top healthcare bets ticking all the boxes for analysts.

Exact Sciences To Host Annual Meeting, Second-quarter 2018 Results Webcasts And Calls

Exact Sciences To Host Annual Meeting, Second-quarter 2018 Results Webcasts And Calls

MADISON, Wis., July 9, 2018 /PRNewswire/ -- Exact Sciences Corp.

Nurse Practitioners Are Critical Source Of Colorectal Cancer Screening Information For Patients, Survey Shows

Nurse Practitioners Are Critical Source Of Colorectal Cancer Screening Information For Patients, Survey Shows

SNAPP Survey Reveals Opportunity for NPs to Help Improve Screening Rates

Cologuard Challenge Expands To AmFam Championship Urging PGA TOUR Champions Fans To Get Screened For Colon Cancer

Cologuard Challenge Expands To AmFam Championship Urging PGA TOUR Champions Fans To Get Screened For Colon Cancer

Fans Signing Pledge will be Entered to Win VIP Experience

Exact Sciences, Mayo Clinic Researchers Identify Blood-Based DNA Biomarker Panel To Accurately Diagnose Hepatocellular Carcinoma

Exact Sciences, Mayo Clinic Researchers Identify Blood-Based DNA Biomarker Panel To Accurately Diagnose Hepatocellular Carcinoma

Data Presented at Digestive Disease Week Show Panel of Six Biomarkers is 95 Percent Sensitive for Most Common Type of Liver Cancer

Exact Sciences To Participate In June Investor Conferences

Exact Sciences To Participate In June Investor Conferences

MADISON, Wis., June 1, 2018 /PRNewswire/ -- Exact Sciences Corp.

Vince Lombardi Cancer Foundation And Exact Sciences Team Up To Fight Colon Cancer

Cologuard named official colon cancer screening partner; VLCF continues national expansion

Nobody Likes Tariffs: Cramer's 'Mad Money' Recap (Thursday 3/1/18)

Nobody Likes Tariffs: Cramer's 'Mad Money' Recap (Thursday 3/1/18)

Nobody likes tariffs, says Jim Cramer. But Trump said he'd do it. Even so, trade and tariff fears have hit Wall Street -- and investors -- hard.

Notable Friday Option Activity: EXAS, GTLS, CARB

Notable Friday Option Activity: EXAS, GTLS, CARB

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in EXACT Sciences Corp. , where a total volume of 12,345 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (given that every 1 contract represents 100 underlying shares).

EXACT Sciences Corp. Larger Than S&P 500 Component Tripadvisor

EXACT Sciences Corp. Larger Than S&P 500 Component Tripadvisor

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component EXACT Sciences Corp. was identified as having a larger market cap than the smaller end of the S&P 500, for example Tripadvisor Inc , according to The Online Investor.

EXACT Sciences: Wait For a Better Buying Opportunity

EXACT Sciences: Wait For a Better Buying Opportunity

The stock still looks vulnerable to further declines from a technical perspective.

Exact Sciences: Cramer's Top Takeaways

Exact Sciences: Cramer's Top Takeaways

Kevin Conroy, chairman and CEO of Exact Sciences, tells Jim Cramer about his company's expansion plans for cancer screening tests.

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

From global growth and bonds to index funds, Jim Cramer explains why stocks keep going up, giving the Dow and Nasdaq their best start to the new year since 2006.

Exact Sciences, Cognizant Technology, MetLife: 'Mad Money' Lightning Round

Exact Sciences, Cognizant Technology, MetLife: 'Mad Money' Lightning Round

Jim Cramer is bullish on Exact Sciences, Cognizant Technology, MetLife, JPMorgan Chase and more.

Sentiment Is Everything Right Now: Cramer's 'Mad Money' Recap (Thursday 11/2/17)

Sentiment Is Everything Right Now: Cramer's 'Mad Money' Recap (Thursday 11/2/17)

Sentiment is critical to the next market move, says Jim Cramer. A little negativity is great news for the bulls.

Noteworthy Monday Option Activity: EXAS, SHAK, ETM

Noteworthy Monday Option Activity: EXAS, SHAK, ETM

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in EXACT Sciences Corp. , where a total volume of 9,758 contracts has been traded thus far today, a contract volume which is representative of approximately 975,800 underlying shares (given that every 1 contract represents 100 underlying shares).

Short Interest Drops 32.5% For EXAS

Short Interest Drops 32.5% For EXAS

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 5,295,292 share decrease in total short interest for EXACT Sciences Corp. , to 10,994,802, a decrease of 32.51% since 09/15/2017.

Short Seller's Critique of Shopify Is 'All Smoke and No Fire'

Short Seller's Critique of Shopify Is 'All Smoke and No Fire'

Analysts, consultants and Shopify users came to the company's defense when TheStreet reached out to them.

TheStreet Quant Rating: D (Sell)